CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Up 5.4% in December

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 19,100,000 shares, a growth of 5.4% from the December 15th total of 18,120,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is currently 11.4 days.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of recent analyst reports. Royal Bank of Canada restated a "sector perform" rating and set a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Bank of America dropped their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. JMP Securities reiterated a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, December 20th. Chardan Capital restated a "buy" rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a research note on Monday, December 30th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $78.38.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded up $0.23 during trading on Friday, reaching $40.53. The company's stock had a trading volume of 1,367,550 shares, compared to its average volume of 1,559,954. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -14.32 and a beta of 1.68. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10. The business's fifty day moving average price is $45.01 and its 200-day moving average price is $48.08.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same period in the previous year, the business posted ($1.41) earnings per share. As a group, sell-side analysts forecast that CRISPR Therapeutics will post -5.13 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 30,000 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the sale, the chief executive officer now owns 196,540 shares in the company, valued at $10,931,554.80. This trade represents a 13.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.10% of the company's stock.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Capital Market Strategies LLC purchased a new position in CRISPR Therapeutics during the fourth quarter worth approximately $461,000. Capital Advisors Inc. OK grew its holdings in CRISPR Therapeutics by 8.1% during the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company's stock valued at $14,122,000 after purchasing an additional 22,583 shares in the last quarter. Geode Capital Management LLC grew its holdings in CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock valued at $47,383,000 after purchasing an additional 35,196 shares in the last quarter. Granite Bay Wealth Management LLC acquired a new stake in CRISPR Therapeutics during the 2nd quarter valued at $2,375,000. Finally, State Street Corp boosted its stake in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after acquiring an additional 599,304 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.